Mountain View, United States
Ainnocence, founded in 2021, is carving a niche at the crossroads of AI and biotechnology. This innovative company, headquartered in the United States, employs its slogan, "AI For Better Medicine," to highlight its mission in transforming the pharmaceutical landscape. At the core of Ainnocence is a robust AI drug design platform capable of virtual screening at unprecedented speeds and optimizing pharmacological profiles for a range of therapeutic modalities.
Their third-generation AI system can analyze up to 1010 protein sequences or chemical compounds in hours, producing candidate shortlists with a high success rate in wet-lab environments. This efficiency translates to reduced drug discovery times and costs, a compelling proposition for stakeholders in the pharmaceutical industry.
With its last known seed investment round on 01 November 2021, led by Genesis Capital, Ainnocence is positioned for scaling its technological and commercial ambitions, appealing to investors interested in AI-driven healthcare solutions.
Sibylla Biotech
